MedKoo Biosciences, Inc.
Tel:   +1-919-636-5577    Fax:   +1-919-980-4831    Email:   sales@medkoo.com
Search
Login Register
Search
MedKoo Cat#: 464187 | Name: Mometasone Furoate-d3
Featured

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Mometasone furoate-d3 is intended for use as an internal standard for the quantification of mometasone furoate by GC- or LC-MS. Mometasone furoate is a prodrug form of the synthetic glucocorticoid mometasone. Intranasal administration of mometasone furoate (1 µg/nostril) reduces the frequency of sneezing and nasal rubbing in a rat model of histamine-induced allergic rhinitis. Topical application of mometasone furoate reduces croton oil-induced ear edema in mice (ED50 = 0.31 µg/ml). Formulations containing mometasone furoate have been used in the treatment of allergic rhinitis, atopic dermatitis, and asthma.

Chemical Structure

Mometasone Furoate-d3
Mometasone Furoate-d3
CAS#unknown

Theoretical Analysis

MedKoo Cat#: 464187

Name: Mometasone Furoate-d3

CAS#: unknown

Chemical Formula: C27H27D3Cl2O6

Exact Mass: 523.1608

Molecular Weight: 524.45

Elemental Analysis: C, 61.84; H, 6.34; Cl, 13.52; O, 18.30

Price and Availability

Size Price Availability Quantity
1mg USD 650.00 2 Weeks
5mg USD 1,650.00 2 Weeks
Bulk Inquiry
Buy Now
Add to Cart
Related CAS #
No Data
Synonym
Mometasone Furoate-d3; Mometasone Furoate d3;
IUPAC/Chemical Name
(8S,9R,10S,11S,13S,14S,16R,17R)-9-chloro-17-(2-chloroacetyl)-11-hydroxy-10,13,16-trimethyl-3-oxo-6,7,8,9,10,11,12,13,14,15,16,17-dodecahydro-3H-cyclopenta[a]phenanthren-17-yl furan-2-carboxylate-d3
InChi Key
WOFMFGQZHJDGCX-VNOPSDMHSA-N
InChi Code
InChI=1S/C27H30Cl2O6/c1-15-11-19-18-7-6-16-12-17(30)8-9-24(16,2)26(18,29)21(31)13-25(19,3)27(15,22(32)14-28)35-23(33)20-5-4-10-34-20/h4-5,8-10,12,15,18-19,21,31H,6-7,11,13-14H2,1-3H3/t15-,18+,19+,21+,24+,25+,26+,27+/m1/s1/i4D,5D,10D
SMILES Code
O=C1C=C[C@]2(C(CC[C@@]3([C@@]2([C@H](C[C@]4([C@]3(C[C@H]([C@@]4(C(CCl)=O)OC(C5=C(C([2H])=C(O5)[2H])[2H])=O)C)[H])C)O)Cl)[H])=C1)C
Appearance
Solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
To be determined
Shelf Life
>2 years if stored properly
Drug Formulation
to be determined
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info
Product Data
Product Data
Instruction
View handling instruction
Biological target:
Mometasone furoate-d3 is a deuterium labeled Mometasone furoate.
In vitro activity:
Cell-based functional systems were established to measure different aspects of GR function, as well as the activity at all the other steroid nuclear receptors. FP (fluticasone propionate) was a relatively weak agonist of the progesterone receptor but MF (mometasone furoate) was a very potent agonist of the progesterone receptor, giving activity at similar concentrations to those that stimulate the GR (concentration generating 50% maximal effect (EC50)=50 pM). Moreover, while FP was a weak antagonist of the mineralocorticoid receptor (concentration generating 50% maximal inhibitory effect=80 nM), MF displayed potent partial agonist activity (EC50=3 nM, 30%). Reference: Eur Respir J. 2002 Dec;20(6):1386-92. https://pubmed.ncbi.nlm.nih.gov/12503693/
In vivo activity:
The aim of the present study was to compare the efficacy of MPSS in respect to other GCs such as dexamethasone (Dex) and mometasone furoate (MF) in an in vitro suitable model of LPS-induced inflammation in J774 cells as well as in an in vivo experimental mouse SCI (compression model). In detail, mice sacrificed seven days after induction of SCI trauma resulted not only in tissue damage, cellular infiltration, fibrosis, astrocyte activation, iNOS expression, extracellular signal regulated kinase 1/2 phosphorylation in injured tissue, poly (ADP-ribose) polymerase 1 (PARP-1) activation but also apoptosis (Bax and Bcl-2 expression). All three GCs demonstrated the ability to modulate inflammatory, oxidative as well as apoptotic pathways, but MF demonstrated the best efficacy, while Dex and MPSS showed alternative potency with a different degree of protection. Reference: Pharmacol Res. 2015 Sep;99:316-28. https://pubmed.ncbi.nlm.nih.gov/26192346/
Solvent mg/mL mM
Solubility
DMSO 6.0 11.44
Note: There can be variations in solubility for the same chemical from different vendors or different batches from the same vendor. The following factors can affect the solubility of the same chemical: solvent used for crystallization, residual solvent content, polymorphism, salt versus free form, degree of hydration, solvent temperature. Please use the solubility data as a reference only. Warming and sonication will facilitate dissolving. Still have questions? Please contact our Technical Support scientists.

Preparing Stock Solutions

The following data is based on the product molecular weight 524.45 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
Formulation protocol:
1. Wang X, Shi J, Gong D. Mometasone furoate inhibits growth of acute leukemia cells in childhood by regulating PI3K signaling pathway. Hematology. 2018 Sep;23(8):478-485. doi: 10.1080/10245332.2018.1436395. Epub 2018 Feb 8. PMID: 29421985. 2. Austin RJ, Maschera B, Walker A, Fairbairn L, Meldrum E, Farrow SN, Uings IJ. Mometasone furoate is a less specific glucocorticoid than fluticasone propionate. Eur Respir J. 2002 Dec;20(6):1386-92. doi: 10.1183/09031936.02.02472001. PMID: 12503693. 3. Galuppo M, Rossi A, Giacoppo S, Pace S, Bramanti P, Sautebin L, Mazzon E. Use of Mometasone furoate in prolonged treatment of experimental spinal cord injury in mice: A comparative study of three different glucocorticoids. Pharmacol Res. 2015 Sep;99:316-28. doi: 10.1016/j.phrs.2015.07.013. Epub 2015 Jul 17. PMID: 26192346. 4. Ogawa M, Sakonjo H, Kamei C. Dissociation of local anti-inflammatory effect and systemic effects of mometasone furoate in mice. Immunopharmacol Immunotoxicol. 2009;31(4):601-6. doi: 10.3109/08923970902874693. PMID: 19874229.
In vitro protocol:
1. Wang X, Shi J, Gong D. Mometasone furoate inhibits growth of acute leukemia cells in childhood by regulating PI3K signaling pathway. Hematology. 2018 Sep;23(8):478-485. doi: 10.1080/10245332.2018.1436395. Epub 2018 Feb 8. PMID: 29421985. 2. Austin RJ, Maschera B, Walker A, Fairbairn L, Meldrum E, Farrow SN, Uings IJ. Mometasone furoate is a less specific glucocorticoid than fluticasone propionate. Eur Respir J. 2002 Dec;20(6):1386-92. doi: 10.1183/09031936.02.02472001. PMID: 12503693.
In vivo protocol:
1. Galuppo M, Rossi A, Giacoppo S, Pace S, Bramanti P, Sautebin L, Mazzon E. Use of Mometasone furoate in prolonged treatment of experimental spinal cord injury in mice: A comparative study of three different glucocorticoids. Pharmacol Res. 2015 Sep;99:316-28. doi: 10.1016/j.phrs.2015.07.013. Epub 2015 Jul 17. PMID: 26192346. 2. Ogawa M, Sakonjo H, Kamei C. Dissociation of local anti-inflammatory effect and systemic effects of mometasone furoate in mice. Immunopharmacol Immunotoxicol. 2009;31(4):601-6. doi: 10.3109/08923970902874693. PMID: 19874229.
1: Youssef YM, Mahrouse MA, Mostafa EA. Plackett-Burman and face-centered composite designs for development and optimization of chromatographic method for the simultaneous determination of glycopyrronium, indacaterol and mometasone in their fixed dose combination inhaler - Green profile assessment. J Pharm Biomed Anal. 2023 Jun 27;234:115553. doi: 10.1016/j.jpba.2023.115553. Epub ahead of print. PMID: 37399700. 2: Kostikas K, Maspero JF, Chapman KR, Mezzi K, Jaumont X, Lawrence D, van Zyl- Smit R. Efficacy of mometasone/indacaterol/glycopyrronium in patients with inadequately controlled asthma with respect to baseline eosinophil count: Post hoc analysis of IRIDIUM study. Respir Med. 2023 Jun 29:107334. doi: 10.1016/j.rmed.2023.107334. Epub ahead of print. PMID: 37392789. 3: Beebeejaun MT, Brown MB, Hutter V, Kravitz L, McAuley WJ. Skin permeation and penetration of mometasone furoate in the presence of emollients: An ex vivo evaluation of clinical application protocols. Skin Health Dis. 2023 Jan 20;3(3):e215. doi: 10.1002/ski2.215. PMID: 37275414; PMCID: PMC10233081. 4: Zimath P, Pinto S, Dias S, Rafacho A, Sarmento B. Zein nanoparticles as oral carrier for mometasone furoate delivery. Drug Deliv Transl Res. 2023 May 19. doi: 10.1007/s13346-023-01367-y. Epub ahead of print. PMID: 37208563. 5: Woehrle H, Mastoridis P, Stempel D, Kaye L, Vuong V, Mezzi K. Medication Adherence and Asthma Control with Once-Daily Indacaterol/Glycopyrronium/Mometasone Furoate Breezhaler Digital Companion: 90-Day Analysis from Germany. Pulm Ther. 2023 Apr 30. doi: 10.1007/s41030-023-00225-z. Epub ahead of print. PMID: 37120785. 6: Ridolo E, Barone A, Nicoletta F, Paoletti G, Heffler E, Malvezzi L, Canonica GW. Intranasal corticosteroid and antihistamine combinations in the treatment of allergic rhinitis: the role of the novel formulation olopatadine/mometasone furoate. Expert Rev Clin Immunol. 2023 Jun;19(6):575-584. doi: 10.1080/1744666X.2023.2200165. Epub 2023 Apr 19. PMID: 37038974. 7: Niimi A, Kanemitsu Y, Tajiri T, Sumi K, Mikami T, Kondo N. Real-life effectiveness of indacaterol/glycopyrronium/mometasone for symptomatic relief of cough after switching from inhaled corticosteroid/long-acting β2-agonist therapy in patients with asthma: REACH study design. ERJ Open Res. 2023 Mar 27;9(2):00452-2022. doi: 10.1183/23120541.00452-2022. PMID: 37009022; PMCID: PMC10052813. 8: Cataldo Russomando A, Steinberg D, Gati I, Vogt Sionov R, Eliashar R, Friedman M, Gross M. Sinonasal Stent Coated with Sustained-Release Varnish of Mometasone Furoate Inhibits Pro-Inflammatory Cytokine Release from Macrophages: An In Vitro Study. Pharmaceutics. 2023 Mar 22;15(3):1015. doi: 10.3390/pharmaceutics15031015. PMID: 36986875; PMCID: PMC10051169. 9: Van Zyl-Smit RN, Kerstjens HA, Maspero JF, Kostikas K, Hosoe M, Tanase AM, D'Andrea P, Mezzi K, Brittain D, Lawrence D, Chapman KR. Efficacy of once-daily, single-inhaler, fixed-dose combination of mometasone/indacaterol/glycopyrronium in patients with asthma with or without persistent airflow limitation: Post hoc analysis from the IRIDIUM study. Respir Med. 2023 May;211:107172. doi: 10.1016/j.rmed.2023.107172. Epub 2023 Mar 9. PMID: 36906187. 10: Zimath PL, Almeida MS, Bruxel MA, Rafacho A. Oral mometasone furoate administration preserves anti-inflammatory action with fewer metabolic adverse effects in rats. Biochem Pharmacol. 2023 Apr;210:115486. doi: 10.1016/j.bcp.2023.115486. Epub 2023 Mar 7. PMID: 36893817. 11: Engineering JOH. Retracted: Treatment Effect of Mometasone Furoate Cream on Lichen Sclerosus et Atrophicus of External Genitalia in Boys and Its Correlation with Toll-Like Receptor 4 and Myeloid Differentiation Factor 88. J Healthc Eng. 2023 Jan 25;2023:9764362. doi: 10.1155/2023/9764362. PMID: 36741875; PMCID: PMC9891809. 12: van Zyl-Smit RN, Chapman KR, Kerstjens HAM, Gessner C, Sagara H, Tanase AM, Hosoe M, Pethe A, Lawrence D, Tillmann HC, D'Andrea P. Mometasone/Indacaterol/Glycopyrronium (MF/IND/GLY) and MF/IND at Different MF Strengths versus Fluticasone Propionate/Salmeterol Xinafoate (FLU/SAL) and FLU/SAL+ Tiotropium in Patients with Asthma. J Asthma Allergy. 2023 Jan 20;16:123-134. doi: 10.2147/JAA.S392975. PMID: 36714049; PMCID: PMC9880009. 13: Fifer S, Toh L, Barkate H, Aggarwal V, Borade D, Gordonsmith RH, Wu W, Morgan C, Young K. Patient Satisfaction and Sensory Attributes of Nasal Spray Treatments of Olopatadine Hydrochloride/Mometasone Furoate Monohydrate and Azelastine Hydrochloride/Fluticasone Propionate for Allergic Rhinitis in Australia - An Observational Real-World Clinical Study. Patient Prefer Adherence. 2023 Jan 15;17:141-151. doi: 10.2147/PPA.S389875. PMID: 36687019; PMCID: PMC9851056. 14: Mehmood Y, Shahid H, Barkat K, Ibraheem M, Riaz H, Badshah SF, Chopra H, Sharma R, Nepovimova E, Kuca K, Valis M, Emran TB. Designing of SiO2 mesoporous nanoparticles loaded with mometasone furoate for potential nasal drug delivery: Ex vivo evaluation and determination of pro-inflammatory interferon and interleukin mRNA expression. Front Cell Dev Biol. 2023 Jan 6;10:1026477. doi: 10.3389/fcell.2022.1026477. PMID: 36684440; PMCID: PMC9853011. 15: Lage NA, de Paiva MRB, Vasconcelos-Santos DV, Machado RR, Fialho SL, Silva- Cunha A. Efficacy and Safety Evaluation of Mometasone Furoate in Treating Ocular Inflammation. Pharmaceutics. 2023 Jan 5;15(1):193. doi: 10.3390/pharmaceutics15010193. PMID: 36678822; PMCID: PMC9863942. 16: Olopatadine/mometasone (Ryaltris) for allergic rhinitis. Med Lett Drugs Ther. 2023 Jan 23;65(1668):12-14. doi: 10.58347/tml.2023.1668c. PMID: 36651792. 17: Baker A, Grobler A, Davies K, Griffiths A, Hiscock H, Kubba H, Peters RL, Ranganathan S, Rimmer J, Rose E, Rowe K, Simpson CM, Davidson A, Nixon G, Perrett KP. Effectiveness of Intranasal Mometasone Furoate vs Saline for Sleep- Disordered Breathing in Children: A Randomized Clinical Trial. JAMA Pediatr. 2023 Mar 1;177(3):240-247. doi: 10.1001/jamapediatrics.2022.5258. PMID: 36648937; PMCID: PMC9857783. 18: Jahani M, Akaberi M, Heidari T, Kamali H, Nejabat M, Rajabi O, Hadizadeh F. Simultaneous determination of mometasone furoate and calcipotriol in a binary mixture by validated HPLC and chemometric-assisted UV spectrophotometric methods and identification of degradation products by LC-MS. Iran J Basic Med Sci. 2023 Jan;26(1):37-47. doi: 10.22038/IJBMS.2022.65436.14396. PMID: 36594065; PMCID: PMC9790053. 19: Taléns-Visconti R, Perra M, Ruiz-Saurí A, Nácher A. New Vehiculation Systems of Mometasone Furoate for the Treatment of Inflammatory Skin Diseases. Pharmaceutics. 2022 Nov 22;14(12):2558. doi: 10.3390/pharmaceutics14122558. PMID: 36559053; PMCID: PMC9786812. 20: Harugop AS, Havaldar RR, Patil PH. Comparison Between Effectiveness of Topical Mometasone Furoate Nasal Spray Versus Topical Fluticasone Furoate Nasal Spray in the Treatment of Chronic Rhinosinusitis: A One Year Hospital Based Study. Indian J Otolaryngol Head Neck Surg. 2022 Oct;74(Suppl 2):821-825. doi: 10.1007/s12070-020-01872-3. Epub 2020 May 6. PMID: 36452763; PMCID: PMC9702125.